Corcept Announces No FDA Advisory Committee Meeting Planned in Connection With New Drug Application for CORLUX for Cushing's Syndrome

Corcept Therapeutics Incorporated CORT today announced that it has been advised by the U.S. Food and Drug Administration that no advisory committee meeting will be scheduled in connection with its review of the New Drug Application for CORLUX, a glucocorticoid receptor type II antagonist, for the treatment of the manifestations of Cushing's Syndrome. This decision does not alter the Prescription Drug User Fee Act goal date for completion of review which remains February 17, 2012.